Posted by Michael Wonder on 03 Jul 2024
Gadopiclenol as an MRI contrast agent: first benefit assessment of a diagnostic agent
1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the framework of AMNOG.
However, the manufacturer did not provide any suitable data to compare direct or therapy-mediated effects of different contrast agents.
